AUS
NZ
UK
CA
USA
IND
Standard BioTools Inc. has finalized the termination of its earnout and royalty obligations with Illumina, Inc., receiving approximately $30 million in cash. Concurrently, the company agreed to divest its mass cytometry business to Multiplex Bio Inc. for $5 million in debt financing plus potential earnout payments. These transactions represent a major portfolio restructuring as Standard BioTools moves forward with its pending merger with Treeline Biosciences.
Key Points
- NASDAQ: LAB
- Standard BioTools received $30 million cash from Illumina in exchange for waiving earnout and royalty payments related to SOMAmer-based products and services
- Mass cytometry business sold to Multiplex Bio for $5 million via promissory note, with an additional potential $5 million contingent earnout over ten years
- Both deals require stockholder approval and completion of the Treeline Biosciences merger
Illumina Deal Ends Future Payment Commitments
On July 24, 2026, Standard BioTools and Illumina executed a Termination, Waiver and Release Agreement, restructuring their prior commercial relationship. Standard BioTools waived its right to a 2026 earnout payment tied to net revenue from SomaScan assay services and SOMAmer-based array and sequencing kits, previously agreed upon in a June 22, 2025 stock purchase agreement. In return, Illumina paid approximately $30 million in cash to Standard BioTools.
Additionally, Standard BioTools terminated the Royalty and License Agreements established on January 30, 2026, which had entitled the company to royalty streams from SOMAmer-based next-generation sequencing library kits and Single SOMAmer reagents. This termination ends future royalty income but provides immediate liquidity amid significant corporate changes.
Mass Cytometry Business Sold to Multiplex Bio
On July 28, 2026, Standard BioTools signed a Share and Asset Purchase Agreement with Multiplex Bio Inc. to sell its mass cytometry business. The agreed purchase price is $5 million on a cash-free, debt-free basis, payable entirely through a promissory note bearing 6% annual interest and maturing five years post-closing. No cash proceeds will be received at closing; instead, Standard BioTools will hold the debt as an asset.
The agreement includes a contingent earnout of up to $5 million if Multiplex Bio completes a qualifying sale exceeding a set threshold within ten years. Multiplex Bio must also attempt to secure a senior secured working capital loan after closing. If unsuccessful despite reasonable efforts, Standard BioTools is obligated to provide up to a $10 million working capital loan at closing. Post-closing, Standard BioTools will offer transition services to support the mass cytometry operations.
Stockholder Approval and Merger Completion Required
Both transactions depend on several conditions, including stockholder approval for the Multiplex Bio sale, which introduces execution risk and timing uncertainty. The mass cytometry sale cannot close until the pending merger with Treeline Biosciences is finalized, linking the two corporate actions.
The purchase agreement allows Standard BioTools' board to seek alternative offers for the mass cytometry business and includes fiduciary-out rights. If a superior unsolicited proposal arises, the board may recommend it, subject to Multiplex Bio's notice and matching rights. The agreement is valid through June 30, 2027, with possible automatic extensions.
Termination Fees and Financial Protections
The agreement stipulates a $1 million termination fee payable by Standard BioTools if the transaction is terminated under certain conditions. Additionally, the company must reimburse Multiplex Bio's reasonable expenses up to $125,000 if the deal does not close by December 31, 2026, and another $125,000 if not closed by March 31, 2027.
These fees compensate Multiplex Bio for transaction costs and lost opportunities, with reimbursements credited against the termination fee, reducing the maximum financial exposure. The staggered reimbursements create intermediate milestones for both parties.
Projected Timeline and Closing Milestones
The deal targets a closing date of June 30, 2027, allowing roughly one year to fulfill conditions and obtain approvals. Automatic three-month extensions may extend the deadline to September 30, 2027, accommodating stockholder approval and the Treeline merger completion.
Standard BioTools must engage stockholders for approval prior to closing the mass cytometry sale. The merger interdependency could delay timelines if either transaction encounters obstacles. Ancillary agreements, including transition services, will be finalized at closing to define post-sale support.
Strategic Impact of Portfolio Realignment
These deals signify a strategic portfolio realignment for Standard BioTools, narrowing its product focus. Divesting the capital-intensive mass cytometry business to Multiplex Bio allows the company to reduce operational scope while retaining potential earnings through the contingent earnout. The promissory note structure provides Multiplex Bio time to integrate and grow the business.
Terminating Illumina payment obligations removes future earnings and royalty accounting complexities. The $30 million cash infusion enhances liquidity to support strategic goals, including the Treeline Biosciences integration. For investors, these moves suggest management’s confidence in a more focused and profitable core business post-merger.
Execution Risks and Investor Considerations
Despite customary deal protections, risks remain. Stockholder approval requirements create uncertainty around the mass cytometry divestiture and strategic direction. Failure to obtain approval could force management to explore alternative options for the business segment.
The linkage to the Treeline merger adds timing complexity, with potential delays cascading between transactions. If Multiplex Bio cannot secure working capital financing and Standard BioTools must provide a $10 million loan, this could affect liquidity and capital allocation. The contingent earnout depends on Multiplex Bio’s successful sale within ten years, outside Standard BioTools’ control.
Deal Structure Insights for Shareholders
The mass cytometry sale consideration is fully deferred via a five-year promissory note, introducing credit risk and timing uncertainty. The 6% interest rate partially compensates for these factors, but investors should evaluate comfort with non-cash consideration. The potential $5 million earnout adds contingent value dependent on market and execution factors.
Conversely, the $30 million Illumina payment is immediate cash, improving liquidity but foregoing future royalty income that could have been significant if SOMAmer products performed well.
Announcement Timing and Regulatory Filings
Standard BioTools announced both transactions on July 28, 2026, coinciding with the Multiplex Bio agreement execution. This followed the Illumina termination agreement dated July 24, 2026, indicating sequential or parallel negotiations finalized on different dates. Disclosures were made via SEC filings, with the Illumina deal reported as a material definitive agreement under Item 1.01 and the press release under Item 7.01.
The announcement includes forward-looking statements subject to the Private Securities Litigation Reform Act of 1995, highlighting projections on divestiture timing, the Treeline merger, and other developments. Investors should be aware actual results may differ materially due to multiple closing conditions and regulatory approvals required.
